Shifting from glucose diagnosis to the new HbA1c diagnosis reduces the capability of the Finnish Diabetes Risk Score (FINDRISC) to screen for glucose abnormalities within a real-life primary healthcare preventive strategy

• Published in: BMC medicine Vol. 11; no. 1; p. 45
• Main Authors: Costa, Bernardo, Barrio, Francisco, Piñol, Josep L, Cabré, Joan J, Mundet, Xavier, Sagarra, Ramon, Salas-Salvadó, Jordi, Solà-Morales, Oriol
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 21.02.2013; BioMed Central
• Subjects: Aged; Blood Glucose; Clinical Medicine - methods; Confidence intervals; Cross-Sectional Studies; Dextrose; Diabetes; Diabetes Mellitus, Type 2 - diagnosis; Diabetes Mellitus, Type 2 - epidemiology; Diabetes Mellitus, Type 2 - pathology; Diabetes Mellitus, Type 2 - prevention & control; Diagnosis; Disease prevention; Epidemiologic Methods; Female; Glucose; Glucose tolerance tests; Glycated Hemoglobin A - analysis; Glycosylated hemoglobin; Health facilities; Health sciences; Humans; Intervention; Life Style; Lifestyles; Male; Medical research; Meetings; Middle Aged; Nutrition; Physiological aspects; Plasma; Population; Prediabetic state; Prevalence; Prevention; Primary care; Primary health care; Primary Health Care - methods; Professional fees; Questionnaires; Risk Assessment; Risk factors; Type 2 diabetes; Spain
• ISSN: 1741-7015; 1741-7015
• DOI: 10.1186/1741-7015-11-45

To investigate differences in the performance of the Finnish Diabetes Risk Score (FINDRISC) as a screening tool for glucose abnormalities after shifting from glucose-based diagnostic criteria to the proposed new hemoglobin (Hb)A1c-based criteria. A cross-sectional primary-care study was conducted as the first part of an active real-life lifestyle intervention to prevent type 2 diabetes within a high-risk Spanish Mediterranean population. Individuals without diabetes aged 45-75 years (n = 3,120) were screened using the FINDRISC. Where feasible, a subsequent 2-hour oral glucose tolerance test and HbA1c test were also carried out (n = 1,712). The performance of the risk score was calculated by applying the area under the curve (AUC) for the receiver operating characteristic, using three sets of criteria (2-hour glucose, fasting glucose, HbA1c) and three diagnostic categories (normal, pre-diabetes, diabetes). Defining diabetes by a single HbA1c measurement resulted in a significantly lower diabetes prevalence (3.6%) compared with diabetes defined by 2-hour plasma glucose (9.2%), but was not significantly lower than that obtained using fasting plasma glucose (3.1%). The FINDRISC at a cut-off of 14 had a reasonably high ability to predict diabetes using the diagnostic criteria of 2-hour or fasting glucose (AUC = 0.71) or all glucose abnormalities (AUC = 0.67 and 0.69, respectively). When HbA1c was used as the primary diagnostic criterion, the AUC for diabetes detection dropped to 0.67 (5.6% reduction in comparison with either 2-hour or fasting glucose) and fell to 0.55 for detection of all glucose abnormalities (17.9% and 20.3% reduction, respectively), with a relevant decrease in sensitivity of the risk score. A shift from glucose-based diagnosis to HbA1c-based diagnosis substantially reduces the ability of the FINDRISC to screen for glucose abnormalities when applied in this real-life primary-care preventive strategy.